跳至主要内容
临床试验/NCT01481727
NCT01481727Unknown4 期

Exacerbation's Prevention in Patients With COPD in GOLD IV Stage (Very Severe) With Non Invasive Mechanical Ventilation

National Institute of Respiratory Diseases, Mexico2 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2011年12月最近更新:
适应症

试验速览

阶段
4 期
入组人数
20
试验地点
2
主要终点
acute exacerbations of Chronic Obstructive Pulmonary Disease frequency

研究概览

简要总结

The purpose of this study is to evaluate the efficacy of high-intensity non invasive mechanical ventilation (during one year to reduce the severity and frequency of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in patients with frequent AECOPD (frequent exacerbations defined more two or more AECOPD) and in GOLD IV stage (very severe COPD). The design is a randomised, double blind and controled with placebo (sham maneuver) clinical trial.

详细描述

Background:

  • There are many previous studies (no controlled trials or observational studies)that demonstrated minimal benefits (on gas exchange and marginal effect over exacerbations frequency) with the use of non invasive mechanical ventilation, in BiPAP modality with IPAP pressures <18H2ocm (low intensity), in COPD patients.
  • In subsequent years there were controled trials that concluded that there was no benefits with the use of non invasive mechanical ventilation on BiPAP mode in COPD patients ( It should be mentioned that in most trials were used low inspiratory pressure levels, that is called low-intensity non invasive mechanical ventilation).
  • However, there are other recent studies that described some benefits of high intensity Bilevel modality of non invasive mechanical ventilation (inspiratory pressures >18cmH2O) specially on gas exchange, quality of life and functional status.
  • There are some issues that do not yet have a clear answer like the optimal inspiratory pressure (IPAP) or the ventilation modality (BIPAP or other) to obtain the maximal benefit on COPD patients. Additionally, is not clear also if the use of non invasive mechanical ventilation on COPD patients helps to reduce the frequency and severity of acute exacerbations of COPD (AECOPD).

This study have some characteristics that are different to the previous reports:

  • The inclusion of patients with frequent exacerbations phenotype (and therefore worst prognosis patients)that there are no included in previous trials
  • The intervention maneuver that is bilevel modality of non invasive mechanical ventilation at hig-intensity pressure (>18H2Ocm and <24H2Ocm)
  • The use of placebo maneuver (CPAP "Sham")
  • The home titration in three phases, over a week
  • The long-term use of the intervention and sham maneuver

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
Double (Participant, Investigator)

入排标准

年龄范围
45 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Clinical and spirometric diagnosis for COPD (FEV1/FVC <70%)
  • Clinical phenotype of frequent exacerbations
  • Must sign the informed consent
  • Former smokers
  • Stable COPD
  • FEV1 <35%
  • Optimal medical treatment

排除标准

  • OSAS diagnosis
  • Other indications for non invasive mechanical ventilation
  • Arterial pressure for dioxide carbon >45mmHg
  • Lung cancer
  • Impossibility for doing spirometry or going to the medical visits
  • Be included in another study

结局指标

主要结局

acute exacerbations of Chronic Obstructive Pulmonary Disease frequency

时间窗: 1 year

It will be calculated the exacerbation/year-patien rate and will be compared between groups

acute exacerbation of chronic obstructive pulmonary disease severity

时间窗: 1 year

It will be measured the rate of AECOPD with hospitalary and Intensive Care Unity requirement

次要结局

  • lymphocyte subpopulations Th-1 and Th-17(1 year)
  • six-minute walking test(1 year)
  • survival(one year)
  • Maximal inspiratory pressure and maximal expiratory pressure(1 año)
  • anxiety and depression measures (HAD and Beck Questionnaires)(one year)
  • Forced expiratory volume in first second (FEV1) and forced expiratory capacity(1 year)
  • gas exchange response (carbon and oxygen dioxide arterial pressure)(1 year)
  • Health related quality of life(one year)
  • echocardiographic parameters(one year)
  • IL-1 and IL-6 cytokines(one year)

研究者

申办方类型
Other Gov
责任方
Principal Investigator
主要研究者

Alejandra Ramirez Venegas

Head of COPD Clinic

National Institute of Respiratory Diseases, Mexico

研究点 (2)

Loading locations...

相似试验